Evidence map›Paper›PMID 39207646›Full record

ReviewClinical reviews in allergy & immunology2024

Methylation of T and B Lymphocytes in Autoimmune Rheumatic Diseases.

Tiantian Deng, Zihan Wang, Qishun Geng, Zhaoran Wang, Yi Jiao, Wenya Diao, Jiahe Xu, Tingting Deng, Jing Luo, Qingwen Tao and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Frontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tiantian DengBeijing University of Chinese Medicine, School of Clinical Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
Zihan WangBeijing University of Chinese Medicine, School of Clinical Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
Qishun GengInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Zhaoran WangInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Yi JiaoBeijing University of Chinese Medicine, School of Clinical Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
Wenya DiaoBeijing University of Chinese Medicine, School of Clinical Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
Jiahe XuChina-Japan Friendship Hospital, Peking University, Beijing, 100029, China.
Tingting DengInstitute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
Jing LuoDepartment of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, 100029, China. luojinggg@sina.com.
Qingwen TaoDepartment of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, 100029, China. taoqg1@sina.com.
Cheng XiaoInstitute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, 100029, China. xc2002812@126.com.

Funding

Capital's Funds for Health Improvement and Research 2024-1-4065Elite Medical Professionals Project of China-Japan Friendship Hospital NO.ZRJY2024-GG08the National High Level Hospital Clinical Research Funding of China-Japan Friendship Hospital 2022-NHLHCRF-LX-02-0103the National High Level Hospital Clinical Research Funding of China-Japan Friendship Hospital 2024-NHLHCRF-JBGS-WZ-02the National Natural Science Foundation of China U22A20374the Rheumatology Branch of the China Association of Chinese Medicine Youth Pei Ying Project No. 202327-007
6 · The paper itself

Abstract

The role of abnormal epigenetic modifications, particularly DNA methylation, in the pathogenesis of autoimmune rheumatic diseases (ARDs) has garnered increasing attention. Lymphocyte dysfunction is a significant contributor to the pathogenesis of ARDs. Methylation is crucial for maintaining normal immune system function, and aberrant methylation can hinder lymphocyte differentiation, resulting in functional abnormalities that disrupt immune tolerance, leading to the excessive expression of inflammatory cytokines, thereby exacerbating the onset and progression of ARDs. Recent studies suggest that methylation-related factors have the potential to serve as biomarkers for monitoring the activity of ARDs. This review summarizes the current state of research on the impact of DNA and RNA methylation on the development, differentiation, and function of T and B cells and examines the progress of these epigenetic modifications in studies of six specific ARDs: systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, systemic sclerosis, juvenile idiopathic arthritis, and ankylosing spondylitis. Additionally, we propose that exploring the interplay between RNA methylation and DNA methylation may represent a novel direction for understanding the pathogenesis of ARDs and developing novel treatment strategies.

Indexed as

Autoimmune DiseasesB-LymphocytesDNA MethylationEpigenesis, GeneticRheumatic DiseasesT-LymphocytesAnimalsHumansAutoimmune rheumatic diseasesEpigeneticsLymphocytesMethylation

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.